Lung Cancer Considered

By IASLCScience

Lung Cancer Considered episodes

July 08, 2024 Lung Cancer Considered in Romanian
Continuing our series of podcasts in different world languages, this episode focuses on lung cancer research and treatment in Romanian.
Host: Mihaela Aldea, MD PhD
Thoracic Oncology and Precision Medicine Group
Department of Medical Oncology
Gustave Roussy, Villejuif, France
Guest: Dr Cristina Ligia Cebotaru, Institute of Oncology 'Prof Dr Ion Chiricuta' Department of Radiotherapy-Medical Oncology, Cluj Napoca
Guest: Dr. Paul Kubelac, Department of Medical Oncology, Institute of Oncology Cluj-Napoca-Romania
36 min
July 02, 2024 The Importance of Waiting for Biomarker Results in NSCLC
Biomarkers are essential in lung cancer treatment, but they remain underutilized. In addition, clinicians and patients have to wait for those results before starting therapy. In this episode of Lung Cancer Considered, host Dr. Stephen Liu guides a discussion about biomarkers and some of the challenges and issues they create.
50 min
June 20, 2024 LCC In Italian--First-Line Treatment Options for EGFR Mutant NSCLC
This episode of Lung Cancer Considered discusses first-line treatment options for EGFR mutant NSCLC, in Italian.
Guest: Dr. Jessica Menis is a thoracic medical oncologist with expertise in early-phase trials and drug development from Azienda Ospedaliera Universitaria Integrata Verona. Jessica, welcome to the podcast.
Guest: Professor Filippo de Marinis is from Istituto Europeo di Oncologia, where he is Direttore della Divisione di Oncologia Toracica, and the president of Associazione Italiana Oncologia Toracica.
48 min
June 18, 2024 FDA Approval Of Tarlartamab
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recently approved bispecific T-cell engager, tarlatamab, for small cell lung cancer.
Guest: Dr. Anne-Marie Dingemans is a pulmonologist and Professor of Thoracic Oncology at Erasmus Medical Center in Rotterdam, the Netherlands.
Guest: Dr.Ryan Gentzler is an Associate Professor and Director of the Thoracic Oncology Clinical Research Program at the University of Virginia
32 min
June 14, 2024 ASCO 2024 Summary Part 2
In episode two summarizing important lung cancer data presented at ASCO 2024, Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu cover the phase III CROWN trial, ROS1 NSCLC with a novel ROS1 TKI, taletrectinib, the MARIPOSA trial, the PALOMA-3 trial, the WU-KONG1 data, the BEAMION-Lung1 trial, and CheckMate 77T.
Guest: Dr. Clarissa Mathias is the Director of NOB/Oncoclinicas in Brazil, a member of the ASCO International Quality Steering Group and Lung Cancer Committee, and a previous IASLC Board Member.
Guest: Dr. Delvys Rodriguez-Abreu is the Head of Medical Oncology at Hospital Universitario Insular de Gran Canaria and President of the Canarian Lung Cancer Foundation.
50 min
June 11, 2024 IASLC - ASCO 2024 Summary--Part 1
Title: ASCO 2024 Highlights Part 1 - Plenary
Description: ASCO 2024 had so much lung cancer data, two podcast episodes are required to cover all the data presented. In this first episode, hosts Dr. Stephen Liu and Dr. Narjust Florez cover the LAURA trial, the ADAURA trial, the KRYSTAL-12 study, the phase III EVOKE-01 trial, the phase III ADRIATIC trial, and the REACH-PC trial.
Guest: Dr. David Spigel is the Chief Scientific Officer at Sarah Cannon Research Institute and recipient of the IASLC Heine H. Hansen Lectureship for SCLC.
Guest: Dr. Lecia Sequist is the Program Director for Cancer Early Detection & Diagnostics at Massachusetts General Cancer Center and the Landry Family Professor of Medicine in the Field of Medical Oncology at Harvard Medical School.
49 min
June 04, 2024 Updates in CT Screening for Lung Cancer
Host Dr. Stephen Liu moderates a discussion of lung cancer screening using low dose CT scans. Low dose CT scans have been shown to detect lung cancer earlier and significantly improve lung cancer mortality. Yet they remain underutilized and are only being used to detect certain types of lung cancer, specifically, smoking-related lung cancer.
Guest: Dr. Pan-Chyr Yang is a Professor and former President of National Taiwan University College of Medicine and recipient of the IASLC Joseph W. Cullen Prevention & Early Detection Award at the 2020 WCLC.
Guest: Dr. Elaine Shum is an Assistant Professor of Medicine at New York University Grossman School of Medicine and Principle Investigator of the Female Asian Nonsmoker Screening Study (FANSS), for which she received the Distinguished Young Investigator Research Award from the EGFR Resisters Summit.
34 min
May 31, 2024 LCC and Smoking Cessation
May 31st is World No Tobacco Day and to observe this, Lung Cancer Considered host Dr. Narjust Florez leads a discussion on smoking cessation and how to honor the need for smoking cessation counseling without contributing to stigma. Smoking tobacco products (primarily cigarettes) is an important risk factor for the development of lung cancer and secondhand smoke is also a significant cause of lung cancer. Worldwide, smoking accounts for approximately two-thirds of lung cancer cases
35 min
May 31, 2024 Lung Cancer Considered--Smoking Cessation
May 31st is World Tobacco Day and the IASLC podcast "Lung Cancer Considered" features a leading expert on smoking cessation, Dr. Kathryn Taylor. Dr. Taylor is behavioral scientist and a Professor in the Department of Oncology at the Georgetown Lombardi Comprehensive Cancer Center in Washington DC Smoking tobacco products (primarily cigarettes) is an important risk factor for the development of lung cancer. Secondhand smoke is also a significant cause of lung cancer. Worldwide, smoking accounts for approximately 2/3 of lung cancer cases with the remaining occurring due to other causes.
35 min
May 24, 2024 LCC in French Canadian
LCC in French Canadian by IASLC
40 min

About Lung Cancer Considered

From the publisher's feed

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.